Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCTC21C in CD38+ Hematologic Malignancies
NCT06252298Phase 1Recruiting
- Sponsor
- Sinocelltech Group Limited
- Start
- Feb 2024
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of SCTC21C in hematologic malignancy, sponsored by Sinocelltech Group Limited. Primary endpoints: Treatment-emergent adverse events and serious adverse events and Incidence of dose limiting toxicities. Started Feb 2024; status: recruiting.
02
Drugs
SCTC21C
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT06252298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06252298.